Phase I to study pharmacokinetics (PK), pharmacodynamics (PD), safety and immunogenicity of proposed biosimilar pegfilgrastim as compared to the reference biologic, Neulasta
Latest Information Update: 20 Jan 2020
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia
- Focus Pharmacodynamics; Pharmacokinetics
- 14 Dec 2019 Results of meta-analysis of three phase I studies ( three arm parallel-group, two-way crossover and three-way crossover) presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 05 Aug 2018 Results published in the British Journal of Clinical Pharmacology.
- 12 Dec 2017 New trial record